A low-grade oncocytic tumor of the kidney (LOT) is a distinctive entity categorized under the 2022 World Health Organization (WHO) classification as "Other oncocytic tumors of the kidney." It represents a unique subset of oncocytic tumors, distinct from oncocytoma and chromophobe renal cell carcinoma. Characterized by bland oncocytic cells that diffusely express CK7 and lack CD117 expression, LOT typically manifests as a solitary, small lesion with a low stage. Available data suggest that LOT follows an indolent clinical course. Herein, we present a case of LOT in a 64-year-old male with a favorable course at a one-year follow-up. Understanding the clinical, morphological, and immunophenotypic features of LOT is paramount for accurate identification and characterization. This knowledge facilitates more conservative surgical and clinical management, optimizing patient care and outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867201 | PMC |
http://dx.doi.org/10.7759/cureus.78132 | DOI Listing |
J Pathol Clin Res
March 2025
1st Pathology Division, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Pulmonary typical carcinoids (TCs) are uncommon, well-differentiated neuroendocrine tumors of the lung that do not exhibit necrosis and have fewer than two mitoses per 2 mm, as defined by the current World Health Organization classifications. Despite their low-grade status and favorable prognostic impact, the protein expression profile and morphological characteristics associated with tumor progression and metastatic spread remain largely unidentified. Oncocytic and spindle cell histological variants are acknowledged for their role in differential diagnosis, though their clinical significance remains a topic of debate.
View Article and Find Full Text PDFVirchows Arch
March 2025
Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Intraductal carcinoma (IDC) of the salivary gland is rare. Histologic subtypes include intercalated duct, oncocytic, apocrine, and hybrid/mixed. Molecular correlates have been described, with intercalated duct IDC typically harboring NCOA4::RET, while TRIM33::RET, or BRAF pathogenic variants predominating in oncocytic IDC.
View Article and Find Full Text PDFCureus
January 2025
Pathology, Temple University, Philadephia, USA.
A low-grade oncocytic tumor of the kidney (LOT) is a distinctive entity categorized under the 2022 World Health Organization (WHO) classification as "Other oncocytic tumors of the kidney." It represents a unique subset of oncocytic tumors, distinct from oncocytoma and chromophobe renal cell carcinoma. Characterized by bland oncocytic cells that diffusely express CK7 and lack CD117 expression, LOT typically manifests as a solitary, small lesion with a low stage.
View Article and Find Full Text PDFDiagn Pathol
February 2025
Department of Diagnostic Pathology, Tokyo Women's Medical University, Adachi Medical Center, Tokyo, Japan.
Background: Low-grade oncocytic tumor (LOT) of the kidney is an emerging entity among renal oncocytic tumors. While the histological features of LOT of the kidney are similar to those of renal oncocytoma, LOT immunohistochemically expresses keratin 7 (KRT7) but not KIT while renal oncocytoma expresses KIT. Molecular analyses of LOTs of the kidney using next generation sequencing revealed those tumors harbor mutations of mTOR-related genes.
View Article and Find Full Text PDFArch Pathol Lab Med
February 2025
From the Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis (Collins, Innani, Saad, Acosta, Baheti, Bakas, Idrees).
Context.—: Distinguishing between renal oncocytic tumors, such as renal oncocytoma (RO), and a subset of tumors with overlapping characteristics, including the recently identified low-grade oncocytic tumor (LOT), can present a diagnostic challenge for pathologists owing to shared histopathologic features.
Objective.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.